CVSI Stock — CV Sciences Inc

CV Sciences Inc (CVSI)

Updated October 16, 2026.

CVSI is a Stock. Total return is -97.3% over the past 14.9 years, 802.0 points behind SPY at 704.7%.

CV Sciences, Inc. develops, manufactures, and markets herbal supplements, hemp-based cannabidiol (CBD) products, and plant-based foods under brands including PlusCBD, PlusHLTH, and Cultured Foods, sold through its websites, distributors, retailers, and e-commerce partners across North America. The company does not currently distribute to shareholders. This company appeals primarily to investors seeking exposure to the CBD and nutraceutical markets rather than those focused on dividend income.

CVSI performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.3% over the past 14.9 years, 802.0 points behind SPY at 704.7%. Over the past year its total return — price change plus distributions reinvested — is -63.7%. Its deepest 1-year drawdown was 88.9%.

CVSI key facts

Asset type

Stock

Asset class

Equity

Inception date

11/09/2011

Distribution frequency

None

Last close

$0.01 (as of 2026-10-16)

Market cap

$3,274,522

Average volume

6120.0

Beta

0.432

Payout ratio

0.0%

Forward P/E

5.1894

EPS

$-0.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CVSI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 88.9%.

Who may consider CVSI — and who may not

It is a weaker fit for investors who need monthly cash flow (CVSI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CVSI

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions